The vaccines currently available provide protection vs. 6, 11, 16, 18, 31, 33, 45, 52, and 58 (type 6 and 11 are responsible for most anogenital warts). Go to footnote 1
Both Bivalent and Quadrivalent Vaccines show cross-protection, with the bivalent vaccine (targeting HPV-16/18) generally provides stronger and more consistent cross-protection, particularly against HPV-31, HPV-33, and HPV-45. Some studies also report partial protection against HPV-35, HPV-52, and HPV-58, though the evidence is less robust and more variable. Go to footnote 2
- Go back to footnote reference 1
HPV vaccines: WHO position paper (https://www.who.int/publications/i/item/who-wer9750-645-672)
Demarco M et al. EClinicalMedicine. 2020, 22:100293 - Go back to footnote reference 2
Tsang, S., Sampson, J., Schussler, J., Porras, C., Wagner, S., Boland, J., Cortés, B., Lowy, D., Schiller, J., Schiffman, M., Kemp, T., Rodriguez, A., Quint, W., Gail, M., Pinto, L., González, P., Hildesheim, A., Kreimer, A., & Herrero, R. (2020). Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: the CVT Trial.. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaa010
